The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Landmark analysis of overall survival (OS) in patients with chronic (CP) or accelerated (AP) phase chronic myeloid leukemia (CML) treated with omacetaxine mepesuccinate.
Meir Wetzler
Consultant or Advisory Role - Teva
Stock Ownership - Teva
Research Funding - Teva
Hagop M. Kantarjian
Research Funding - Teva
Franck E. Nicolini
Consultant or Advisory Role - Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Novartis
Jeffrey Howard Lipton
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Luke Paul Akard
Honoraria - Teva
Michele Baccarani
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Hanna Jean Khoury
Consultant or Advisory Role - Pfizer
Elizabeth Li
Consultant or Advisory Role - PharmaStat
Mihaela C. Munteanu
Employment or Leadership Position - Teva
Stock Ownership - Teva
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva